Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. — VialBase Research

Summary

Subarachnoid hemorrhage is an acute neurological condition associated with high mortality and high rates of recovery failure, although mortality after SAH has fallen in recent years with the development of endovascular and classical surgical techniques. As attention shifts toward the molecular mechanisms underlying SAH and toward treatments that improve outcome rather than survival alone, Cerebrolysin — a mixture of neuropeptides with properties similar to neurotrophic factors — has been used in stroke including SAH. The authors note that although Cerebrolysin’s impact in stroke generally has been analysed, no meta-analysis in the existing literature had addressed the subpopulation of patients diagnosed specifically with subarachnoid hemorrhage, and they conducted this synthesis of available clinical trials to fill that gap. Their reported result is that the data suggest a positive effect of Cerebrolysin on mortality in SAH patients. The authors immediately qualify it: further randomised clinical trials with larger groups of patients are needed to draw final conclusions. The abstract as indexed does not report pooled effect sizes, confidence intervals, the number of included studies, or the total participant count, and the review was published in Journal of Clinical Medicine rather than through the Cochrane process, so it carries no GRADE certainty ratings or formal systematic risk-of-bias assessment.

Key Findings

• First meta-analysis to address the subarachnoid hemorrhage subpopulation specifically; the authors state no prior SAH-only meta-analysis existed
• Pooled data suggest a positive effect of Cerebrolysin on mortality in SAH patients
• Cerebrolysin is described as a mixture of neuropeptides with properties similar to neurotrophic factors, already used in stroke including SAH
• The authors state directly that further randomised clinical trials with larger patient groups are needed before final conclusions can be drawn
• Published outside the Cochrane process, with no GRADE certainty ratings; the indexed abstract reports no pooled effect estimates, confidence intervals, study count, or participant total

Relevance to Cerebrolysin

Of the four clinical syntheses in the Cerebrolysin file, this is the narrowest in scope and the most provisional in its own framing. A suggested mortality benefit in subarachnoid hemorrhage is a genuinely interesting signal — mortality is a hard endpoint, not a rated scale — and it deserves to be recorded rather than dismissed. But the authors themselves stop short of a conclusion, calling explicitly for larger randomised trials, and the indexed abstract does not supply the pooled effect size, confidence interval, or number of contributing studies that would let a reader judge the strength of the finding. It also sits well below the Cochrane reviews in evidence grade: no GRADE ratings, no published risk-of-bias table, and a subpopulation small enough that no one had previously attempted to pool it. This note is best used as a marker that SAH is an open research question for Cerebrolysin, not as support for a clinical claim. Where a Cerebrolysin claim needs backing, the Cochrane reviews on acute ischaemic stroke and vascular dementia remain the governing evidence, and both are unfavourable.

Citation

Kojder K, Jarosz K, Bosiacki M, et al. Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. Journal of clinical medicine. 2023;12(20). doi:10.3390/jcm12206638.

See Also

• Parent compound: Cerebrolysin